Positive developments priced in; time to take profits
29/10/26 -"After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% downside. Although the positive readouts have ..."
Pages
54
Language
English
Published on
29/10/26
You may also be interested by these reports :
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...
28/10/26
The Q3 profitability exceeded expectations, though sales came in line with consensus. The strong showing in ‘Specialty medicines’ made up for the ...
28/10/26
The Q3 sales missed consensus because of near-term biosimilar supply constraints, pricing pressure in Germany and lower prices for penicillin APIs – ...
27/10/26
The Q3 results were ahead of the street’s expectations, as generic erosion of a major heart failure drug was more than compensated for by robust ...